ADC Therapeutics SA Operating Income 2019-2023 | ADCT
ADC Therapeutics SA operating income from 2019 to 2023. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
ADC Therapeutics SA Annual Operating Income
(Millions of US $) |
| 2022 |
$-124 |
| 2021 |
$-262 |
| 2020 |
$-219 |
| 2019 |
$-119 |
| 2018 |
$-126 |
ADC Therapeutics SA Quarterly Operating Income
(Millions of US $) |
| 2023-03-31 |
$-52 |
| 2022-12-31 |
$-11 |
| 2022-09-30 |
$-3 |
| 2022-06-30 |
$-69 |
| 2022-03-31 |
$-40 |
| 2021-12-31 |
$-63 |
| 2021-09-30 |
$-58 |
| 2021-06-30 |
$-70 |
| 2021-03-31 |
$-71 |
| 2020-12-31 |
$-78 |
| 2020-09-30 |
$-52 |
| 2020-06-30 |
$-45 |
| 2020-03-31 |
$-44 |
| 2019-12-31 |
|
| 2019-09-30 |
$-33 |
| 2019-06-30 |
$-24 |
| 2018-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.191B |
$0.210B |
|
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
|
